The ATHENA X-ray Integral Field Unit (X-IFU)

The X-ray Integral Field Unit (X-IFU) is the high resolution X-ray spectrometer of the ESA Athena X-ray observatory. Over a field of view of 5' equivalent diameter, it will deliver X-ray spectra from 0.2 to 12 keV with a spectral resolution of 2.5 eV up to 7 keV on ∼ 5" pixels. The X-IFU is based on a large format array of super-conducting molybdenum-gold Transition Edge Sensors cooled at ∼ 90 mK, each coupled with an absorber made of gold and bismuth with a pitch of 249 μm. A cryogenic anti-coincidence detector located underneath the prime TES array enables the non X-ray background to be reduced. A bath temperature of ∼ 50 mK is obtained by a series of mechanical coolers combining 15K Pulse Tubes, 4K and 2K Joule-Thomson coolers which pre-cool a sub Kelvin cooler made of a 3He sorption cooler coupled with an Adiabatic Demagnetization Refrigerator. Frequency domain multiplexing enables to read out 40 pixels in one single channel. A photon interacting with an absorber leads to a current pulse, amplified by the readout electronics and whose shape is reconstructed on board to recover its energy with high accuracy. The defocusing capability offered by the Athena movable mirror assembly enables the X-IFU to observe the brightest X-ray sources of the sky (up to Crab-like intensities) by spreading the telescope point spread function over hundreds of pixels. Thus the X-IFU delivers low pile-up, high throughput (< 50%), and typically 10 eV spectral resolution at 1 Crab intensities, i.e. A factor of 10 or more better than Silicon based X-ray detectors. In this paper, the current X-IFU baseline is presented, together with an assessment of its anticipated performance in terms of spectral resolution, background, and count rate capability. The X-IFU baseline configuration will be subject to a preliminary requirement review that is scheduled at the end of 2018

On the Apparent Absence of Wolf-Rayet plus Neutron Star Systems: The Curious Case of WR124

© 2018. The American Astronomical Society. All rights reserved.. Among the different types of massive stars in advanced evolutionary stages is the enigmatic WN8h type. There are only a few Wolf-Rayet (WR) stars with this spectral type in our Galaxy. It has long been suggested that WN8h-type stars are the products of binary evolution that may harbor neutron stars (NS). One of the most intriguing WN8h stars is the runaway WR 124 surrounded by its magnificent nebula M1-67. We test the presence of an accreting NS companion in WR 124 using ∼100 ks long observations by the Chandra X-ray observatory. The hard X-ray emission from WR 124 with a luminosity of L X ∼ 1031 erg s-1 is marginally detected. We use the non-local thermodynamic equilibrium stellar atmosphere code PoWR to estimate the WR wind opacity to the X-rays. The wind of a WN8-type star is effectively opaque for X-rays, hence the low X-ray luminosity of WR 124 does not rule out the presence of an embedded compact object. We suggest that, in general, high-opacity WR winds could prevent X-ray detections of embedded NS, and be an explanation for the apparent lack of WR+NS systems.status: publishe

Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome

\ua9 The Author(s) 2023. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: [email protected]. BACKGROUND: The prognosis for Li-Fraumeni syndrome (LFS) patients with medulloblastoma (MB) is poor. Comprehensive clinical data for this patient group is lacking, challenging the development of novel therapeutic strategies. Here, we present clinical and molecular data on a retrospective cohort of pediatric LFS MB patients. METHODS: In this multinational, multicenter retrospective cohort study, LFS patients under 21 years with MB and class 5 or class 4 constitutional TP53 variants were included. TP53 mutation status, methylation subgroup, treatment, progression free- (PFS) and overall survival (OS), recurrence patterns, and incidence of subsequent neoplasms were evaluated. RESULTS: The study evaluated 47 LFS individuals diagnosed with MB, mainly classified as DNA methylation subgroup "SHH_3" (86%). The majority (74%) of constitutional TP53 variants represented missense variants. The 2- and 5-year (y-) PFS were 36% and 20%, and 2- and 5y-OS were 53% and 23%, respectively. Patients who received postoperative radiotherapy (RT) (2y-PFS: 44%, 2y-OS: 60%) or chemotherapy before RT (2y-PFS: 32%, 2y-OS: 48%) had significantly better clinical outcome then patients who were not treated with RT (2y-PFS: 0%, 2y-OS: 25%). Patients treated according to protocols including high-intensity chemotherapy and patients who received only maintenance-type chemotherapy showed similar outcomes (2y-PFS: 42% and 35%, 2y-OS: 68% and 53%, respectively). CONCLUSIONS: LFS MB patients have a dismal prognosis. In the presented cohort use of RT significantly increased survival rates, whereas chemotherapy intensity did not influence their clinical outcome. Prospective collection of clinical data and development of novel treatments are required to improve the outcome of LFS MB patients